Biotech | April 05, 2022
Lupin signs deal with Alvion for cardiometabolic drugs in Southeast Asia
Lupin is committed to providing new affordable treatment options to healthcare providers and patients
Lupin is committed to providing new affordable treatment options to healthcare providers and patients
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
It is currently available in tablet and injectable dosage forms
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
The company inaugurated the new production line at the Bengaluru facility to manufacture Computed Tomography Scanners
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
It also secures US $ 10 million for US launch and commercialization
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
Supply increase to help meet growing global demand
Sanofi’s DE&I Board will include three of the most influential voices in the DE&I space as Board members appointed for 3 years: organizational psychologist & best-selling author John Amaechi, award-winning social entrepreneur Caroline Casey, and DE&I pioneer and renowned thought-leader Dr. Rohini Anand
Subscribe To Our Newsletter & Stay Updated
